



SECOND TRADEMARK OFFICE PTO FORM-1449 INFORMATION DISCLOSURE CITATION		Inventor: KAUTZ		Art Unit: XX	
		Appl. No.: 10/590,803		Examiner: XX	
		Filing Date: August 25, 2006		Confirm. No.: XX	
		U.S. PATENT DOCUMENTS			
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
FOREIGN PATENT DOCUMENTS					
Exam. Initial		Document No.	Public. Date	Country	Translation
OTHER					
Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)				
	A34	Souness, J.E., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors", <u>Immunopharmacology</u> , Vol. 47, Pg. 127-162, (2000).			
	A35	Dyke, H.J., et al., "Update on the therapeutic potential of PDE4 inhibitors", <u>Expert Opin. Investig. Drugs</u> , Vol. 11, No. 1, Pg. 1-13, (2002).			
	A36	Montana, J.G., et al., "Chapter 5. Phosphodiesterase 4 Inhibitors", <u>Annual Reports in Medicinal Chemistry</u> , Vol. 36, Pg. 41-56, (2001).			
	A37	Schmidt, B.M.W., et al., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis", <u>J Allergy Clin Immunol</u> , Vol. 108, Pg. 530-536, 2001).			
Examiner /Marcos Sznaidman/				Date Considered 04/05/2011	
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					